The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)

Overview of attention for article published in Cancer Communications, November 2019

Altmetric Badge

Mentioned by

So far, Altmetric has seen 1 news story.

Gefitinib (Iressa) was the first epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for the…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.